/Companies

Jasper Therapeutics

NASDAQ: JSPR

Redwood City, US · Delaware corporation · 4 known investors

Find your way into Jasper Therapeutics

317 people in our graph share verified history with the Jasper Therapeutics team — schools, employers, funds. One of them is your warm intro.

Ronald Martellunlockedknows Herb Cross · together at Jasper Therapeutics (overlapped)
knows the team · via Atreca, Inc.
knows the team · via The Association of Bioscience Financial Officers International
×9knows the team · via Navigant Consulting

Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases. The company is running clinical studies in chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma.

Founders & leadership

JS
Judith ShizuruFounder
HCHerb Cross
Herb CrossChief Financial OfficerHerb Cross is Chief Financial Officer at Jasper Therapeutics, a biopharmaceutical company developing a monoclonal antibody candidate for mast cell-driven diseases. He has held CFO positions at multiple life sciences companies including Atreca, ARMO BioSciences, Balance Therapeutics, KaloBios Pharmaceuticals, and Affymax, and previously served as Vice President of Finance at Neoforma, PDL BioPharma, and Facet Biotech; he holds a BS in Business Administration from UC Berkeley and is a Certified Public Accountant.
JMJeet Mahal
Jeet MahalChief Executive OfficerJeet Mahal has over thirty years of experience in biotechnology and pharmaceutical development and commercialization, including operational roles at biotech startups and consulting engagements with major public firms. He holds an MBA, a Master's degree in Molecular Biology, and a Master's degree in Engineering, along with an undergraduate degree in Molecular Biology.
PCPatrick Crutcher
Patrick CrutcherNamed on SEC filing
SLSvetlana Lucas
Svetlana LucasNamed on SEC filing
WS
Wenru SongNamed on SEC filing
GF
Gregory F. KeenanNamed on SEC filing

Board

KVKurt von Emster
Kurt von EmsterBoard MemberManaging Partner at Abingworth
TWThomas Wiggans
Thomas WiggansBoard director
ME
Matthew E. RosBoard director

Investors · 4

Reported raises · per SEC filings

Form D private placements

$132M disclosed across 1 round · 2026

▶$132MraisedAug 2026 · 40 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Herb CrossExecutive Officer
  • Jeet MahalExecutive Officer, Director
  • Patrick CrutcherDirector
  • Thomas WiggansDirector
  • Judith ShizuruDirector
  • Svetlana LucasDirector
  • Kurt von EmsterDirector
  • Wenru SongExecutive Officer
  • Gregory F. KeenanExecutive Officer
  • Matthew E. RosDirector
Offering amount
$132M
Amount sold
$132M
First sale
Jul 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Companies competing with Jasper Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Jasper Therapeutics do?
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases. The company is running clinical studies in chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma.
Who founded Jasper Therapeutics?
Jasper Therapeutics was founded by Judith Shizuru.
Who are Jasper Therapeutics's investors?
Jasper Therapeutics's investors include Avego BioScience Capital, TSVC, Abingworth, Ikarian Capital.
How much funding has Jasper Therapeutics raised?
Jasper Therapeutics has disclosed $132M raised across 1 round.
Where is Jasper Therapeutics headquartered?
Jasper Therapeutics is headquartered in Redwood City, US.